Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone Irrigations for Cortisol Suppression in Chronic Rhinosinusitis
NCT03979209Phase 1Completed
- Sponsor
- Rush University Medical Center
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Mometasone furoate nano-nasal spray in chronic rhinosinusitis (CRS) (3 arms), sponsored by Rush University Medical Center. Primary endpoint: Morning 'AM' Serum Cortisol Level at 12 weeks. Started Jan 2019; status: completed.
02
Drugs
Mometasone furoate nano-nasal spray
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT03979209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979209.